MPT-0118 is under clinical development by Monopteros Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MPT-0118’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MPT-0118 is under development for the treatment of advanced or metastatic refractory solid tumors. It is administered through oral route and acts by targeting mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1).
For a complete picture of MPT-0118’s drug-specific PTSR and LoA scores, buy the report here.